ACTIV-3 has claimed yet another victim. Molecular Partners and Novartis are the latest companies to fail to clear the efficacy bar in the NIH-sponsored COVID-19 study, leaving their hopes for…
AavantiBio has hired its sixth key executive this year with the addition of former bluebird bio VP Jenny Marlowe as chief scientific officer. Marlowe joins the one-year-old startup after helping…
Recognized as Method of the Year by Nature in 2020, spatial transcriptomics employs advanced imaging methods with novel chemistry techniques that stand to dramatically expand our understanding of…
By creating a focused approach to the transition to the home and often prolonged recovery journey, while taking each person’s life context into account, we can make sure that no patient feels…
Cala Health, a company with a wearable device for essential tremor, recently raised $77 million in funding. It plans to expand to more indications and seek more coverage of its device with the funds.
The company’s co-founders are leaving the company as it struggles with retention and billing, with revenue coming short of expectations for the quarter. In the interim, Chairman Doug Braunstein will…
Terry Lo Terry Lo is President and CEO of Vizgen: the company setting the standard in spatial genomics by commercializing the MERSCOPE Platform, the industry’s first massively multiplexed, spatially resolved, single-cell genomics imaging tool. At Vizgen, Terry leverages two decades of leadership experience to scale growth of the company and drive the commercial development of …
Flagship Pioneering’s Valo Health and Khosla Ventures Acquisition Co. abandoned their SPAC merger on the eve of a scheduled shareholder vote on whether to approve the deal. The parties described the…
Dr. Alan Spiro Dr. Alan Spiro is a leader in healthcare delivery and management, with more than 40 years of clinical, analytics, marketing, management and operational experience. He is currently the President and Chief Medical Officer of Laguna Health, a digital-first recovery platform. He most recently served as a clinical advisor and fractional Chief Medical …
Acelyrin has in-licensed izokipeb, an antibody drug developed by Affibody that could offer advantages compared to currently available monoclonal antibodies. The drug addresses the same target as blockbuster immunology drugs marketed by Novartis and Eli Lilly.
